Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

NCT00699790 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: CCR2 Antagonist
DRUG: Placebo

Sponsor

Bristol-Myers Squibb